# Zenas BioPharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zenas-biopharma

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.zenasbio.com/
- Total disclosed funding: $318M
- Latest round: Series C (May 3, 2024)
- Investors on record: 20

## About

Founded in 2019 by Lonnie Moulder Jr, and based in Massachusetts, US, Zenas BioPharma (USA) LLC operates as a biopharmaceutical company dedicated to developing and delivering immune-based treatments to people. In May 2024, Zenas BioPharma (USA) LLC raised USD 200.15 million in Series C funding co-led by SR One, New Enterprise Associates, Norwest Venture Partners, Delos Capital Partners, and others. In September 2024, Zenas BioPharma, Inc. raised USD 209 million in an IPO, selling 13.23 million shares at USD 17 per share, within the expected USD 16-18 range, on the Nasdaq Global Select Market under the ticker symbol "ZBIO." BioPharma, Inc. has granted the underwriters a 30-day option to purchase up to an additional 1.98 million shares of common stock as part of the listing. Following the transaction, Xencor, Inc. retained a 7.8% minority stake, Enavate Sciences retained a 7.2% minority stake, SR One retained a 6.7% minority stake, and Longitude Capital retained a 5.2% minority stake, respectively. 

Zenas BioPharma is a clinical-stage biopharmaceutical company developing and commercializing immunology-based therapies for autoimmune diseases. The company offers a portfolio of therapeutics in clinical development, targeting areas with significant unmet medical needs. Zenas provides transformative treatments to improve the lives of patients with autoimmune conditions.

The company intends to use the May 2024 funding to support the mid to late-stage clinical trials for its lead product candidate drug, obexelimab bifunctional monoclonal antibody.

## Funding rounds

- Series C, May 3, 2024, $200M — New Enterprise Associates, Norwest Venture Partners, SR One, Vivo Capital, Wellington Management, Longitude Capital, ArrowMark Partners, Rock Springs Capital, Federated Hermes, Delos Capital Partners, Fairmount Funds Management, Pivotal Life Sciences, Quan Capital, Enavate Sciences, Superstring Capital Management
- Series B, Nov 7, 2022, $118M — Vivo Capital, Wellington Management, Longitude Capital, Xencor, Inc., Rock Springs Capital, Perceptive Advisors, Fairmount Funds Management, Pivotal Life Sciences, Agent Capital, Quan Capital, Tellus BioVentures, Enavate Sciences, Superstring Capital Management
- Series A, Mar 23, 2021 — Wellington Management, 6 Dimensions Capital, Fairmount Funds Management, Quan Capital, Tellus BioVentures

## Investors

- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series A, Series B, Series C
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series A
- Fairmount Funds Management — Series A, Series B, Series C
- Quan Capital (https://capitalatlas.ai/funds/quan-capital) — Series A, Series B, Series C
- Tellus BioVentures (https://capitalatlas.ai/funds/tellus-bioventures) — Series A, Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series B, Series C
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series B, Series C
- Xencor, Inc. — Series B
- Rock Springs Capital — Series B, Series C
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- Pivotal Life Sciences (https://capitalatlas.ai/funds/pivotal-life-sciences) — Series B, Series C
- Agent Capital (https://capitalatlas.ai/funds/agent-capital) — Series B
- Enavate Sciences — Series B, Series C
- Superstring Capital Management (https://capitalatlas.ai/funds/superstring-capital-management) — Series B, Series C
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series C
- Norwest Venture Partners (https://capitalatlas.ai/funds/norwest-venture-partners) — Series C
- SR One (https://capitalatlas.ai/funds/sr-one) — Series C
- ArrowMark Partners — Series C
- Federated Hermes (https://capitalatlas.ai/funds/federated-hermes) — Series C
- Delos Capital Partners (https://capitalatlas.ai/funds/delos-capital-partners) — Series C